Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Toshihiro Hama"'
Autor:
Takeshi Aoyama, Kenji Nakano, Takeshi Yuasa, Erika Sugiyama, Takako Okawa, Kazuyuki Ito, Keiichi Azuma, Koki Hashimoto, Ryota Furutani, Makoto Hiraide, Kazuo Kobayashi, Kenichi Suzuki, Jyunnichi Tomomatsu, Masataka Tajima, Hitoshi Sato, Toshihiro Hama, Shunji Takahashi
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract The safety and effectiveness of pazopanib are related to plasma trough concentrations in renal cell carcinoma (RCC); however, data on pazopanib plasma trough concentrations with soft tissue sarcoma (STS) are limited. This study investigated
Externí odkaz:
https://doaj.org/article/980b2c0f97b242018c4d72bbb6d25e96
Autor:
Yusuke Iikura, Takeshi Aoyama, Makoto Hiraide, Takeru Wakatsuki, Izuma Nakayama, Mariko Ogura, Akira Ooki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Toshihiro Hama
Publikováno v:
Health Science Reports, Vol 5, Iss 4, Pp n/a-n/a (2022)
Abstract Background and Aims This study aimed to examine the safety of fixed‐dose nivolumab. Methods We retrospectively reviewed the medical records of 113 Japanese patients with gastric cancer who were previously treated with cytotoxic chemotherap
Externí odkaz:
https://doaj.org/article/b2b34521a95d4e6aad402f4e1d4af7b9
Autor:
Masahiro Hatori, Kazuyoshi Kawakami, Takeru Wakatsuki, Eiji Shinozaki, Kazuo Kobayashi, Takeshi Aoyama, Yasuhiro Nakano, Kenichi Suzuki, Kensei Yamaguchi, Toshihiro Hama
Publikováno v:
Dose-Response, Vol 19 (2021)
The association between regorafenib dosage in the treatment of metastatic colorectal cancer (mCRC) and efficacy is currently not well established. It was previously reported that the regorafenib dose as prescribed is associated with efficacy, but dos
Externí odkaz:
https://doaj.org/article/9d6ff2fccdd846bdb56396ca0adfff74
Autor:
Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Koichi Goto, Reiko Matsui, Nobuhiko Seki, Toshikazu Shimada, Shunya Ikeda, Naoki Ikegami, Toshihiro Hama, Nobuyuki Yamamoto, Tadanori Sasaki
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 4, Iss 1, Pp 1-9 (2018)
Abstract Background We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant
Externí odkaz:
https://doaj.org/article/5b0a5c8ba430476091d421c82a65f915
Autor:
Genta Ito, Kazuyoshi Kawakami, Takeshi Aoyama, Takashi Yokokawa, Masashi Nakamura, Masato Ozaka, Naoki Sasahira, Masayuki Hashiguchi, Hayato Kizaki, Toshihiro Hama, Satoko Hori
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0254726 (2021)
AimCombination therapy with gemcitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel), known as GnP therapy, significantly prolongs the survival of pancreatic cancer patients compared with gemcitabine monotherapy. However, it may cause s
Externí odkaz:
https://doaj.org/article/cc96a8ba7c564820827eaff691150d08
Autor:
Kazuyoshi Kawakami, Terumasa Chiba, Nobuyuki Katagiri, Maya Saduka, Kenji Abe, Iku Utsunomiya, Toshihiro Hama, Kyoji Taguchi
Publikováno v:
Journal of Pharmacological Sciences, Vol 120, Iss 3, Pp 187-195 (2012)
Peripheral neuropathic pain is a serious side effect of paclitaxel treatment. However, the mechanism of this paclitaxel-induced neuropathic pain is unknown. In this study, we investigated the effects of paclitaxel on the voltage-dependent calcium cha
Externí odkaz:
https://doaj.org/article/1170680d97ff44c7b8d8959c1c2d0b1e
Autor:
Yoshimi Haga, Masaki Yamada, Risa Fujii, Naomi Saichi, Takashi Yokokawa, Toshihiro Hama, Yoshihiro Hayakawa, Koji Ueda
Publikováno v:
Analytical chemistry. 94(46)
The glycoform of a therapeutic monoclonal antibody (mAb) has a significant impact on its effector function as well as its safety and pharmacokinetics. Glycoform heterogeneity is influenced by various factors, including the producing cells and cell cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72090f2f74b2ae43f3078e27ab8cfd40
https://pubmed.ncbi.nlm.nih.gov/36345688
https://pubmed.ncbi.nlm.nih.gov/36345688
Autor:
Moemi, Kawaguchi, Kazuyoshi, Kawakami, Takeshi, Aoyama, Takuya, Tomomatsu, Toshihiro, Hama, Daisuke, Takahari, Keisho, Chin, Kensei, Yamaguchi, Masakazu, Yamaguchi
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 49(8)
Hypertension is one of the main side effects of ramucirumab(RAM)plus paclitaxel(PTX)therapy. Although dihydropyridine calcium channel blockers(D-CCBs)are considered to cause drug-drug interactions with PTX based on the inhibition of cytochrome P450,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51deff4571715c03b87c14bbf41547d1
https://pubmed.ncbi.nlm.nih.gov/36046973
https://pubmed.ncbi.nlm.nih.gov/36046973
Autor:
Koki Hashimoto, Erika Sugiyama, Mitsukuni Suenaga, Kazuyoshi Kawakami, Hiyori Kidokoro, Takeru Wakatsuki, Masataka Tajima, Keisho Chin, Eiji Shinozaki, Hitoshi Sato, Takashi Ichimura, Yuichi Minowa, Wataru Suzuki, Yasuhiro Nakano, Izuma Nakayama, Kazuo Kobayashi, Mariko Ogura, Toshihiro Hama, Daisuke Takahari, Akira Ooki, Tomoko Hiraoka, Kensei Yamaguchi, Takashi Yokokawa, Takeshi Aoyama, Kenichi Suzuki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:767-777
The association between the pharmacokinetics and pharmacodynamics of regorafenib, a multiple tyrosine kinase inhibitor, remains unclear. This study assessed the trough plasma concentrations (Ctrough) of regorafenib and its N-oxide (M2) and N-oxide/de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1414a8d60a33ea5f0ecd45f3a5647e0a
https://doi.org/10.1007/s00280-021-04237-x
https://doi.org/10.1007/s00280-021-04237-x
Autor:
Yoshinori Ito, Kazuo Kobayashi, Kazuyoshi Kawakami, Toshihiro Hama, Shunji Takahashi, Takeshi Aoyama, Kokoro Kobayashi, Shinji Ohno, Takashi Yokokawa, Daigo Shouji, Kenichi Suzuki, Tomomi Takiguchi, Hiroshi Watanabe, Takahito Sugisaki
Publikováno v:
Anticancer Research. 40:915-921
BACKGROUND/AIM This study aimed was to clarify the impact of pegfilgrastim (PEG) 3.6 mg primary prophylaxis of febrile neutropenia (FN) on the average relative dose intensity (ARDI) of neoadjuvant/adjuvant FEC-100 for breast cancer. MATERIALS AND MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06dfca2daca06d960ee825648e3adebf
https://doi.org/10.21873/anticanres.14024
https://doi.org/10.21873/anticanres.14024